Our news

ZENEO® Midazolam earns the orphan drug designation

The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.

Read more

ZENEO® receives the JANUS

Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design. 

Conference room

Conference calendar

Starting in autumn, Crossject will be attending renowned international conferences in Europe and the United States.

Crossject is recruiting

As a rapidly developing company, Crossject is looking to recruit new team members with a range of profiles to respond to its growing business needs.